Key Highlights
- Helus Pharma (NASDAQ:HELP) announced on November 16, 2026 that HLP003 achieved its primary objective in the Phase 3 APPROACH study of major depressive disorder.
- HLP003 patients saw depression scores improve 19.5 points versus 11.9 for placebo after six weeks, a 7.6 point gap, and benefit was visible from day two.
- Prior to the open, the stock ranged from USD 4.85 to USD 11.22 relative to a USD 8.87 previous close, and the session ended with a 13.53% decline.
- Topline data from EMBRACE, a second pivotal study, are due in the fourth quarter of 2027.
What the Study Found
Researchers in APPROACH enrolled 222 adults who had moderate to severe major depressive disorder and had not responded well enough to the antidepressant they were already taking. Everyone stayed on that treatment and was assigned either HLP003 or placebo alongside it. The company describes HLP003 as designed to promote neuroplasticity; it is a deuterated form of psilocin, a serotonergic compound related to the active ingredient in psilocybin. The FDA has granted it Breakthrough Therapy Designation for this use. The MADRS depression scale served as the main measure. At six weeks, HLP003 lowered scores by 19.5 points and placebo by 11.9, leaving a highly statistically significant 7.6 point difference. Benefit arrived fast, with a 5.0 point gap on day two, and it held at 12 weeks, when the gap stood at 7.0 points. Response rates at six weeks were 56.3% for HLP003 and 28.2% for placebo, while remission reached 50.9% versus 18.2%. For people who have already failed at least one standard antidepressant, those are strong numbers. Three serious adverse events were reported as related to treatment, and the company said no new safety signals emerged.
Explaining the Drop in the Shares
Price action was extreme. Before the market opened the stock whipsawed between USD 4.85 and USD 11.22, having closed at USD 8.87 on November 13. It climbed about 15% early, sank about 30% at one point, turned briefly positive and then sold off again, finishing 13.53% lower. Nobody offered a single explanation, and several factors probably combined. High expectations ahead of the readout meant some holders sold on the news, a familiar pattern when a much-awaited result lands. Although limited, the three treatment-related serious adverse events could raise doubts over how regulators will judge safety for a drug of this class, which normally calls for supervised dosing. Some investors may also be weighing the expense and inconvenience of in-clinic treatment against oral antidepressants. Heavy selling in Growth Stocks that day, with the Nasdaq Composite down 2.49%, made speculative names harder to hold up as well. And when a large Volume of orders hits at once, thin premarket Liquidity can magnify the swings.
The Road Ahead for HLP003
In depression, approval rarely rests on one positive Phase 3 trial. Helus is running EMBRACE, a second pivotal study with topline results expected in the fourth quarter of 2027, along with an extension study named EXTEND that follows long-term safety, durability and repeat dosing. The eventual filing package will take shape from these studies, and no date has been given yet for a new drug application. APPROACH offers the programme a solid foundation, notably through the quick onset and the remission rates. Investors will want to know whether EMBRACE confirms the benefit, how frequently patients need repeat doses and which monitoring regulators will require. Financing deserves attention too, since late-stage psychiatry trials cost a great deal and a sell-off makes raising Capital pricier. Given the Volatility of November 16, the shares will probably remain sensitive to further detail from medical meetings or regulatory updates.
Where Things Stand
Helus delivered a clearly positive Phase 3 result, yet the stock closed lower after a chaotic session. The market appears focused on safety, practicality and the need for a second trial. EMBRACE results in late 2027 are the next major test.






Please wait processing your request...